Reportlinker Adds GlaxoSmithKline plc: PharmaVitae Profile

NEW YORK, Nov 03, 2009 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue.

GlaxoSmithKline plc: PharmaVitae Profile http://www.reportlinker.com/p0157541/GlaxoSmithKline-plc-PharmaVitae-Profile.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire Introduction This analysis examines the historical and forecast performance for GSK in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase *Benchmark GlaxoSmithKline's performance against key rivals in the prescription pharmaceutical sector *Assess the threat posed by generic competition to GlaxoSmithKline's core prescription pharmaceutical business *Analyze the future strategic direction of GSK, namely an enhanced vaccine offering, geographic diversification and increased biologics presence ABOUT DATAMONITOR HEALTHCARE 2 About the PharmaVitae team 2 Chapter 1 About this profile 3 PharmaVitae Explorer database 3 Chapter structure 3 Executive summary 3 Quarterly news update 3 Company introduction 3 Company sales 4 Company financials 4 Key products and competitors 4 Data sourcing 4 Sales data 4 Analyst consensus 4 Chapter 2 Executive summary 5 Key findings 5 Prescription pharmaceutical sales and growth rate performance, 2002-14 6 Financial performance, 2002-14 7 GlaxoSmithKline: PharmaVitae forecasts at a glance 8 Strategic insight 9 Introduction 9 Analysis of sales performance 2002-08 9 Analysis of sales performance 2008-14 10 Outlook 14 SWOT analysis 16 Strengths 17 Weaknesses 18 Opportunities 18 Threats 20 TABLE OF CONTENTS 22 Table of figures 24 Chapter 3 Quarterly news update 25 Product developments 25 Deals and alliances 27 Product deals 27 Technology deals 32 M&A activity 33 Company announcements 33 Future product milestones 35 Chapter 4 Company introduction 38 Key findings 38 Background 39 M&A history 39 Glaxo and Wellcome 39 Glaxo Wellcome 39 Smith Kline and Beecham 39 SmithKline Beecham 40 Key historical drug launches by component GSK companies 41 M&A strategy 41 R&D overview 44 Chapter 5 Company sales 46 Key findings 46 Prescription pharmaceutical sales and growth rate analysis, 2002-14 47 Product analysis 49 Product analysis, 2002-08 50 Product analysis, 2008-14 53 Therapy area analysis 56 Geographic analysis 59 Launch/core/expiry analysis 61 Explanation of launch/core/expiry analysis 61 Launch analysis, 2008-14 62 Core analysis, 2008-14 65 Expiry analysis, 2008-14 66 Launch/core/expiry configuration, 2008-14 68 Molecule type analysis 69 Externalization analysis 73 Chapter 6 Company financials 76 Key findings 76 Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 77 Operating costs and profit analysis 78 Operating costs and profit analysis, 2002-08 79 Operating cost ratio and profit margin analysis, 2002-08 80 Operating cost ratio and profit margin analysis, 2008-14 81 Operating costs and profit analysis, 2008-14 82 Chapter 7 Key products and competitors 83 Overview 83 Respiratory 84 Seretide/Advair 84 Overview 84 Sales forecast 85 Beyond Advair 87 Overview 87 Sales forecast 88 Infectious diseases 89 Cervarix 89 Overview 89 Sales forecast 90 Valtrex 93 Overview 93 Sales forecast 94 Oncology 95 Tykerb/Tyverb 95 Overview 95 Sales forecast 96 Genitourinary 98 Duodart 98 Overview 98 Sales forecast 99 Central Nervous system 100 Almorexant 100 Overview 100 Sales forecast 101 Lamictal 102 Overview 102 Sales forecast 103 Imigran/Imitrex 105 Overview 105 Sales forecast 106 Endocrinology 108 Avandia 108 Overview 108 Sales forecast 109 Chapter 8 Appendix 112 R&D pipeline 112 Abbreviations 115 Exchange rates 116 About Datamonitor 117 About Datamonitor Healthcare 117 Datamonitor consulting 117 Disclaimer 119 LIST OF TABLES Table 1: GlaxoSmithKline - PharmaVitae forecasts at a glance 8 Table 2: GlaxoSmithKline vaccine sales ($m), 2008-14 13 Table 3: GlaxoSmithKline key product developments, 2009 25 Table 4: GlaxoSmithKline product deals and alliances, 2009 27 Table 5: GlaxoSmithKline technology deals and alliances, 2009 32 Table 6: GlaxoSmithKline M&A activity, 2009 33 Table 7: GlaxoSmithKline company announcements, 2009 33 Table 8: GlaxoSmithKline future product milestones, 2009-11 35 Table 9: GlaxoSmithKline product portfolio overview ($m), 2002-08 50 Table 10: GlaxoSmithKline product portfolio overview ($m), 2008-14 53 Table 11: GlaxoSmithKline prescription pharmaceutical sales by therapy area ($m), 2008-14 57 Table 12: GlaxoSmithKline prescription pharmaceutical sales by geographic region ($m), 2008-14 60 Table 13: GlaxoSmithKline launch portfolio overview ($m), 2008-14 62 Table 14: GlaxoSmithKline core portfolio overview ($m), 2008-14 65 Table 15: GlaxoSmithKline expiry portfolio overview ($m), 2008-14 66 Table 16: GlaxoSmithKline prescription pharmaceutical sales by molecule type ($m), 2008-14 70 Table 17: GlaxoSmithKline vaccine sales ($m), 2008-14 71 Table 18: GlaxoSmithKline prescription pharmaceutical sales by source ($m), 2008-14 74 Table 19: Total GlaxoSmithKline sales by business unit ($m), 2002-08 77 Table 20: GlaxoSmithKline operating revenue/cost analysis ($m), 2002-08 79 Table 21: GlaxoSmithKline operating cost ratio analysis (% of total revenues), 2002-08 80 Table 22: GlaxoSmithKline operating cost ratio analysis (% of total revenues), 2008-14 81 Table 23: GlaxoSmithKline operating revenue/cost analysis ($m), 2008-14 82 Table 24: GlaxoSmithKline Key products overview 83 Table 25: Seretide/Advair: overview 84 Table 26: Seretide/Advair: sales forecast ($m), 2008-14 85 Table 27: Beyond Advair: overview 87 Table 28: Beyond Advair: sales forecast ($m), 2008-14 88 Table 29: Cervarix: overview 89 Table 30: Cervarix: sales forecast ($m), 2008-14 90 Table 31: Valtrex: overview 93 Table 32: Valtrex: sales forecast ($m), 2008-14 94 Table 33: Tykerb/Tyverb: overview 95 Table 34: Tykerb/Tyverb: sales forecast ($m), 2008-14 96 Table 35: Duodart: overview 98 Table 36: Duodart: sales forecast ($m), 2008-14 99 Table 37: Almorexant: overview 100 Table 38: Almorexant: sales forecast ($m), 2008-14 101 Table 39: Lamictal: overview 102 Table 40: Lamictal: sales forecast ($m), 2008-14 103 Table 41: Imigran/Imitrex: overview 105 Table 42: Imigran/Imitrex: sales forecast ($m), 2008-14 106 Table 43: Avandia: overview 108 Table 44: Avandia: sales forecast ($m), 2008-14 109 Table 45: GlaxoSmithKline's R&D pipeline (Phase I-registration) 112 Table 46: Exchange rates, 2009 116 LIST OF FIGURES Figure 1: The PharmaVitae Explorer 3 Figure 2: GlaxoSmit6thKline prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6 Figure 3: GlaxoSmithKline's financial performance ($m), 2002-14 7 Figure 4: GlaxoSmithKline launch/core/expiry configuration ($m), 2002-08 9 Figure 5: GlaxoSmithKline launch/core/expiry configuration ($m), 2008-14 10 Figure 6: GlaxoSmithKline prescription pharmaceutical sales growth by molecule type ($m), 2008-14 12 Figure 7: GlaxoSmithKline SWOT analysis 16 Figure 8: M&A/divestment history 40 Figure 9: GlaxoSmithKline prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 47 Figure 10: Key product sales ($m), 2002-14 49 Figure 11: GlaxoSmithKline key sales growth drivers and resistors ($m), 2002-08 52 Figure 12: GlaxoSmithKline key sales growth drivers and resistors ($m), 2008-14 55 Figure 13: GlaxoSmithKline prescription pharmaceutical sales by therapy area ($m), 2002-14 56 Figure 14: GlaxoSmithKline prescription pharmaceutical sales by geographic region ($m), 2002-14 59 Figure 15: GlaxoSmithKline launch/core/expiry configuration ($m), 2008-14 68 Figure 16: GlaxoSmithKline prescription pharmaceutical sales by molecule type ($m), 2002-14 69 Figure 17: GlaxoSmithKline prescription pharmaceutical sales by source ($m), 2002-14 73 Figure 18: GlaxoSmithKline operating revenue/cost analysis ($m), 2002-14 78 To order this report: GlaxoSmithKline plc: PharmaVitae Profile http://www.reportlinker.com/p0157541/GlaxoSmithKline-plc-PharmaVitae-Profile.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire More market research reports here! Nicolas Bombourg Reportlinker Email: [e-mail] US: [phone] Intl: [phone] SOURCE Reportlinker www.prnewswire.com Copyright (C) 2009 PR Newswire. All rights reserved -0- INDUSTRY KEYWORD: HEA

MTC SUBJECT CODE: SVY